YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World's First In Vivo Gene Editing Therapy for PH1
SHANGHAI,Aug. 22,2024--YolTech Therapeutics,a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures,today announced a major milestone: the first patient has been dosed